Deramiocel Cuts Myocardial Fibrosis, Boosts LVEF by 3.3 Points and Slows DMD 83%
Capricor’s Phase 3 HOPE-3 trial of Deramiocel in Duchenne muscular dystrophy showed a three-segment reduction in myocardial fibrosis (p=0.022) and a 3.3-point LVEF gain versus placebo (p=0.017). The GST composite favored Deramiocel (p=0.017) and the Duchenne Video Assessment showed 83% slowed progression (p=0.018) before the August 2026 FDA PDUFA date.
1. Cardiac Outcomes in HOPE-3 Trial
The Phase 3 HOPE-3 trial demonstrated Deramiocel’s impact on cardiac structure in Duchenne muscular dystrophy patients. Cardiac MRI analysis revealed a three-segment reduction in late gadolinium enhancement–defined myocardial fibrosis (p=0.022) and a 3.3-point improvement in left ventricular ejection fraction versus placebo (p=0.017) in those with baseline cardiomyopathy.
2. Functional and Composite Benefits
A Global Statistical Test composite endpoint, integrating Performance of Upper Limb, LVEF, and Patient Global Impression of Severity, showed a statistically significant overall benefit for Deramiocel (p=0.017). The Duchenne Video Assessment further demonstrated an 83% slowing of disease progression on an "eat 10 bites" task compared with placebo (p=0.018).
3. Regulatory Status and Next Steps
Deramiocel’s Biologics License Application is under FDA review with a PDUFA target action date of August 22, 2026. Capricor is preparing for potential approval interactions and remains focused on bringing this therapy to Duchenne patients pending regulatory clearance.